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Hamburg, GermanyObjectives This study sought to report on the feasibility and early results of transcatheter aortic valve
implantation employing a second-generation device in a series of patients with pure aortic
regurgitation.
Background Efﬁcacy and safety of transcatheter aortic valve implantation in patients with calciﬁc
aortic stenosis and high surgical risk has been demonstrated. However, experience with implantation
for severe noncalciﬁed aortic regurgitation has been limited due to increased risk for valve dislocation
or annular rupture.
Methods Five patients (mean age: 66.6  7 years) underwent transapical implantation of a JenaValve
(JenaValve Technology GmbH, Munich, Germany) transcatheter heart valve for moderate to severe,
noncalciﬁed aortic regurgitation. All patients were considered high risk for surgical aortic valve
replacement after evaluation by an interdisciplinary heart team (logistic EuroSCORE [European System
for Cardiac Operative Risk Evaluation] range 3.1% to 38.9%). Procedural and acute clinical outcomes
were analyzed.
Results Implantation was successful in all cases without relevant remaining aortic regurgitation or
signs of stenosis in any of the patients. No major device- or procedure-related adverse events occurred
and all 5 patients were alive with improved exercise tolerance at 3-month follow-up.
Conclusions Noncalciﬁed aortic regurgitation continues to be a challenging pathology for
transcatheter aortic valve implantation due to the risk for insufﬁcient anchoring of the valve stent
within the aortic annulus. This report provides ﬁrst evidence that the JenaValve prosthesis may be
a reasonable option in these speciﬁc patients due to its unique stent design, clipping the native aortic
valve leaﬂets, and offering promising early results. (J Am Coll Cardiol Intv 2013;6:590–7) ª 2013 by
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assist device
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valve implantation
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591Efﬁcacy and safety of transcatheter aortic valve implantation
(TAVI) in patients with severe aortic stenosis and contra-
indications or high risk for conventional surgery have been
demonstrated (1,2). However, off-label treatment of severe
noncalciﬁed aortic regurgitation using the self-expanding
Medtronic CoreValve prosthesis (Medtronic, Minneapolis,
Minnesota) or the balloon-expandable Edwards Sapien XT
valve (Edwards Lifesciences, Irvine, California) has only been
described infrequently (3–6). Although feasibility has been
demonstrated, pure regurgitation poses a challenge on TAVI
due to the absence of annular or leaﬂet calciﬁcations required
for secure anchoring of transcatheter heart valves (THV),
increasing the risk of dislocation.
With the recent CE-mark (Conformité Européenne)
approval of second-generation devices for TAVI, new stent
designs and technologies have become available. The Jena-
Valve prosthesis (JenaValve Technology GmbH, Munich,
Germany) features a unique clip ﬁxation mechanism of the
native aortic valve leaﬂets that may offer secure anchorage of
the THV even in the absence of calciﬁcations (7). Therefore,
this device may be an appropriate option, even in patients
with noncalciﬁed aortic regurgitation.
We report for the ﬁrst time on the feasibility and early
results of TAVI using the JenaValve THV in a series of
patients with pure aortic regurgitation.
Methods
Patient population and diagnostic work-up. Between
September 2007 and December 2012, 750 TAVI procedures
have been performed at our institution, almost exclusively for
severe symptomatic aortic stenosis. From May through
September 2012, 5 patients were admitted; 4 presented with
symptomatic noncalciﬁed aortic regurgitation, and 1 patient
with severe heart failure scheduled for implantation of a left
ventricular assist device (LVAD) and concomitant moderate
aortic regurgitation. All patients presented with severe
comorbidities or previous operations, yielding an increased
operative risk for surgical aortic valve replacement as deter-
mined by an interdisciplinary heart team (Table 1). In addi-
tion to routine work-up, pre-operative transesophageal
echocardiography was performed to determine valve
pathology and to assess ventricular function and dimensions.
The aortic annulus diameter was measured in the short-axis
view. Aortic regurgitation was assessed in the parasternal
long-axis view and graded according to the Doppler vena
contracta width (8,9). Additionally, the color Doppler jet
width was indexed to the left ventricular outﬂow tract width,
as obtained in the parasternal short-axis view (9,10). A
contrast-enhanced multislice computed tomography with
prospective electrocardiogram-gating was employed to assess
aortic valve and root morphology (Fig. 1). Area- and perim-
eter-derived aortic annulus diameters, optimal C-arm angu-
lation, and transapical access location were determined usingthe 3mensio valves software (3mensio Medical Imaging BV,
Bilthoven, the Netherlands), as previously described (11).
Procedure. TAVI was performed in a specially equipped
hybrid suite under general anesthesia by an interdisciplinary
heart team of cardiac surgeons, interventional cardiologists,
and anesthesiologists. Transapical access was gained in the
usual fashion through a left lateral minithoracotomy and
purse-string sutures were applied to the left ventricular apex.
The delivery catheter was introduced and positioned over a
stiff guidewire. The THV size was selected according to
the annulus diameters gained from multislice computed
tomography. Following the manufacturer’s recommenda-
tions, a 23-mm prosthesis was chosen for an aortic annulus of
21 to 22.9mm, a 25-mmprosthesis for an aortic annulus of 23
to 24.9 mm, and a 27-mm prosthesis for an aortic annulus of
25 to 27 mm. Anatomically oriented implantation of the
JenaValve prosthesis, a trileaﬂet porcine root tissue valve
attached to a nitinol stent, was performed without the use of
rapid ventricular pacing under ﬂuoroscopic control (Fig. 2,
Online Video 1), as previously described (12). Brieﬂy, the
delivery catheter with the loaded JenaValve prosthesis was
advanced through the native valve into the ascending aorta and
the positioning feelers were
released and placed into the cor-
responding sinuses of the aortic
root. After correct orientation had
been veriﬁed in 2 different ﬂuo-
roscopic angulations, the lower
stent part was subsequently
released, resulting in the clipping
and attachment of the non-
calciﬁed aortic valve leaﬂets to the device and expansion of the
stent. Subsequently, valve performance was assessed by
transesophageal echocardiography and ﬂuoroscopy. We
refrained from balloon valvuloplasty of the native aortic valve
before THV implantation except for 1 patient with secondary
commissural fusion (Patient #2). In another patient, TAVI
was followed by subsequent implantation of an LVAD
(HVAD, HeartWare, Framingham, Massachusetts).
Data management and clinical follow-up. All relevant base-
line, procedural, and follow-up data were prospectively
collected. Clinical and echocardiographic examinations were
performed prior to discharge, at 30 days, and at 3 months.
Outcomes were analyzed in accordance with the updated
standardized endpoints deﬁned by the Valve Academic
Research Consortium-2 consensus document (13).
Ethics. All patients were fully informed about the procedure
and this off-label use of the THV, and they signed written
consent forms.
Results
Baseline characteristics. Five patients (mean age: 66.6 
7 years, 80% men) presented with noncalciﬁed aortic
valve
Table 1. Baseline Clinical Parameters
Patient #
Age,
yrs Sex
BMI,
kg/m2
Log ES,
%
STS-PROM,
%
NYHA
Class Comorbidities
Creatinine,
mg/dl
PAP,
mm Hg
MR
Grade
TR
Grade
EF,
%
1 70 Male 25.8 11.0 1.8 3 Coronary artery disease, status after myocardial infarction and
coronary artery bypass grafting, arterial hypertension
0.9 22 1 0 52
2 72 Male 20.2 11.4 6.3 4 Severe COPD requiring home oxygen therapy, coronary artery
disease, atrial ﬁbrillation, previous stroke, arterial hypertension
0.7 60 2–3 2 78
3 72 Male 22.9 38.9 7.0* 4 Severe ischemic cardiomyopathydscheduled for LVAD
implantation, coronary artery disease with previous myocardial
infarction, status after mitral valve repair and coronary artery
bypass grafting, diabetes mellitus, atrial ﬁbrillation, prior
implantation of AICD, porcelain aorta
1.0 65 3 2 20
4 56 Female 39.0 3.1 3.0 3 History of adrenal carcinoma with subsequent unilateral
nephrectomy and Cushing disease, pneumonia, and sepsis with
respiratory failure, diabetes mellitus, arterial hypertension
1.1 48 1 1 51
5 62 Male 24.4 33.9 3.5 4 NSTEMI with subsequent resuscitation, PCI, 2 months prior
to procedure, prolonged ICU care with pneumonia and
respiratory failure, coronary artery disease, rheumatoid arthritis,
prior implantation of AICD, porcelain aorta
0.7 60 1–2 2 28
*STS-PROM calculated for isolated TAVI procedure due to nonavailability for combined TAVI and LVAD implantation.
AICD ¼ automated internal cardioverter-deﬁbrillator; BMI¼ body mass index; COPD ¼ chronic obstructive pulmonary disease; EF ¼ left ventricular ejection fraction; log ES ¼ logistic European System for
Cardiac Operative Risk Evaluation (EuroSCORE); ICU ¼ intensive care unit; LVAD ¼ left ventricular assist device; MR ¼ mitral regurgitation; NSTEMI ¼ non–ST-segment elevation myocardial infarction;
NYHA ¼ New York Heart Association functional class; PAP ¼ systolic pulmonary artery pressure; STS-PROM ¼ Society of Thoracic Surgeons Predicted Risk of Mortality; TAVI ¼ transcatheter aortic valve
implantation; TR ¼ tricuspid regurgitation.
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592regurgitation due to different etiologies. Four patients
were highly symptomatic for severe aortic regurgitation
(Fig. 3), and 1 patient was scheduled for LVAD-implantation
for end-stage heart failure with concomitant moderate aorticFigure 1. Aortic Valve Morphology
Baseline computed tomography scan for assessment of aortic valve morphology and
level (A, B, C) and corresponding coronal views (D, E, F) of Patient #1 (A, D), Patienregurgitation. This patient had an indication for aortic valve
replacement (Fig. 4) because even moderate aortic regurgita-
tion can result inmalfunction of theLVAD.Due to a porcelain
aorta, aortic cross clamping for surgical aortic valveannular measurements. Multiplanar reconstruction in axial views at the Valsalva
t #2 (B, E), and Patient #3 (C, F).
Figure 2. Step-by-Step Implantation
Step-by-step transapical implantation (in Patient #1) of a 27-mm JenaValve prosthesis (JenaValve Technology GmbH, Munich, Germany): Aortic root shot conﬁrming
severe aortic regurgitation (A). The delivery catheter with the loaded valve prosthesis is advanced through the native valve into the ascending aorta (B). The
positioning feelers are released, checked for correct orientation, and placed into the aortic root (C). Release of the lower stent part results in the clipping and
attachment of the native aortic valve leaﬂets to the device and expansion of the stent (D). Complete deployment after release of the upper stent part (E) and
aortography performed to assess valve function (F) (Online Video 1).
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593replacement was precluded, yielding a hybrid approach of
transapical TAVI and LVAD implantation in this particular
case (Patient #3). The remaining 4 patients underwent TAVI
without additional procedures. All patients were evaluated by
an interdisciplinary heart team and deemed eligible for
a transcatheter approach due to comorbidities resulting in
excessive operative risk, which was not necessarily reﬂected by
the commonly used risk stratiﬁcation tools (mean logistic
EuroSCORE [European System for Cardiac Operative Risk
Evaluation] range: 3.1% to 38.9%, STS-PROM [Society of
Thoracic Surgeons Predicted Risk of Operative Mortality]
range: 1.8% to 7%). Despite low risk scores, 1 patient (Patient
#1) was deemed eligible for a transcatheter approach due to
patent bypass grafts after coronary artery bypass surgery several
years ago. Detailed patient characteristics are listed in Table 1;
aortic valve speciﬁcations are listed in Table 2.
Procedural outcomes and valve function. TAVI using the
JenaValve second-generation THV was performed success-
fully in all 5 patients without hemodynamic compromise
or the need for extracorporeal circulation. A 27-mm devicewas chosen in 4 patients and a 23-mm device in 1 patient
according to aortic annulus measurements by multislice
computed tomography and transesophageal echocardiog-
raphy (Table 2). Procedure times ranged from 55 to 90 min
(Table 3). No post-dilation was necessary in any of the
cases. Echocardiographic evaluation after TAVI ruled out
relevant aortic regurgitation or signs of aortic stenosis in all
patients (Figs. 3 and 4). Left ventricular end-diastolic
diameters remained fairly unchanged at this early stage after
implantation.
Clinical outcomes and follow-up. No major procedure- or
device-related adverse events occurred during 3-month
follow-up. According to the Valve Academic Research
Consortium-2 document, 3 patients suffered from acute
kidney injury stages 1 or 2. One patient with pre-existing
pulmonary disease and home oxygen therapy suffered from
severe pneumonia and subsequent sepsis after discharge that
eventually resolved under antibiotic treatment. No new-
onset conduction disturbances, yielding a permanent pace-
maker implantation, or bleeding complications were
Figure 3. Echocardiographic Valve Performance
Echocardiographic evaluation depicting severe noncalciﬁed central aortic regurgitation before transcatheter aortic valve implantation (A, B). Color Doppler conﬁrms
optimal function of the implanted 27-mm JenaValve transcatheter heart valve. No paravalvular leaks are detected (C, D) (Patient #2).
Figure 4. TAVI and Concomitant LVAD Implantation
Moderate central aortic regurgitation prior to implantation of a left ventricular assist device (LVAD) (A, B). In anticipation of worsening aortic regurgitation and
hemodynamic compromise during LVAD support, a 27-mm JenaValve prosthesis was implanted transapically beforehand. Color Doppler conﬁrms optimal function of
the implanted transcatheter heart valve (C, D) (Patient #3). TAVI ¼ transcatheter aortic valve implantation.
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Table 3. Procedural and Follow-Up Parameters
Procedure 3-Month Follow-Up
Patient #
Procedure
Time,
min
Fluoroscopy
Time,
min
Contrast
Medium,
ml BAV Adverse Events
NYHA
Class
AR
Grade
1 60 4.4 200 None None 1 None
2 85 5.7 149 Once Acute kidney injury
stage 2,* severe
pneumonia and
sepsis requiring
antibiotic therapy
3 Trace
3 55 7.1 140 None Acute kidney injury
stage 1,* LVAD
driveline infection
requiring surgical
revision
3 None
4 90 7.2 309 None Acute kidney injury
stage 1*
1 None
5 60 5.2 202 None Pleural effusion
requiring drainage
2 Trace
*According to the Valve Academic Research Consortium-2 consensus document.
BAV ¼ balloon aortic valvuloplasty; other abbreviations as in Tables 1 and 2.
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595observed. Device success was achieved in all patients,
whereas the combined 30-day safety endpoint was not met
in any of the cases. All 5 patients were alive with improved
exercise tolerance at 3 months (Table 3).
Discussion
According to recent guidelines (14), aortic valve surgery is
recommended in patients with chronic severe aortic regur-
gitation and subsequent symptoms or impaired left
ventricular function (Class IB indication). If patients are not
considered surgical candidates, however, therapeutic options
are scarce. Noncalciﬁed or predominant aortic regurgitation
has typically been considered a contraindication for TAVI
(15) due to the risk of valve dislocation as a consequence of
insufﬁcient anchoring.
Few cases have been published describing the off-label use
of currently available THV devices in patients with pure
aortic regurgitation. Several groups used the Medtronic
CoreValve prosthesis for implantation (3,5,6) because
additional anchorage of the valve stent in the left ventricular
outﬂow tract and ascending aorta may offer sufﬁcient
stability. Others have reported the implantation of an
Edwards Sapien prosthesis employing substantial oversizing
(4), accepting a signiﬁcant hazard for annular rupture or
incomplete valve expansion. Limitations are obvious to both
approaches because either THV was designed for implan-
tation into calciﬁed aortic valves through radial expansion at
the annular plane level.
In contrast, the JenaValve system relies on a feeler-guided
positioning and a clip ﬁxation mechanism of the native
aortic valve leaﬂets, allowing for anatomically correct and
secure implantation even in the absence of annular or leaﬂet
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596calciﬁcations (7). Therefore, this THV may be particularly
suitable for patients with predominant or pure aortic
regurgitation. Additionally, there is no need for oversizing,
alleviating the risk of annular dilation or rupture after TAVI
in patients with noncalciﬁed aortic annuli. In the absence of
calciﬁcations, no balloon valvuloplasty of the native aortic
valve is necessary before implantation. We performed pre-
ballooning only in 1 patient who was noted to have partially
fused left and noncoronary cusps. No rapid ventricular
pacing is needed during valve deployment, allowing for
beating-heart implantation, hence adding safety to the
procedure especially in patients with hemodynamic
compromise or depressed left ventricular function.
Early promising results with the JenaValve THV in
patients with aortic stenosis have been published as part of
the ﬁrst-in-man (16) and CE-mark trials (12). Long-term
data are currently being investigated within the JUPITER
(Longterm Safety and Performance of the JenaValve;
NCT01598844) study. As for all other valve types, patients
with very inhomogeneous calciﬁcation patterns may not be
ideal candidates for this THV and the stent design essen-
tially precludes the JenaValve implantation in certain
morphologies, such as bicuspid aortic valves. Additionally,
dilated aortic roots with annuli exceeding a diameter of
27 mm should be avoided to prevent valve dislocation or
suboptimal function. Dilation of the ascending aorta is not
a contraindication for the JenaValve prosthesis because valve
implantation does not require extensive manipulation in the
ascending aorta. However, a dilated ascending aorta
exceeding 5 cm in diameter should be considered as an
indication for surgical replacement of the aorta, at least in
patients with acceptable operative risk.
Beyond that, and for the ﬁrst time, this report highlights
the feasibility of implanting a JenaValve prosthesis in patients
with noncalciﬁed aortic regurgitation. Despite the small
number of patients, hemodynamic and clinical outcomes were
promising in this series without any major procedure- or
device-related adverse events during early follow-up. The
straightforward implantation technique and excellent acute
resultsmay establish aortic regurgitation as a new indication for
this device. However, before recommending broad application
for noncalciﬁed aortic regurgitation (off-label use), longer-
term follow-up and larger patient numbers should be awaited.
Study limitations. Despite the obvious limitations of this
study, certain factors may make patients with pure aortic
regurgitation particularly suitable for transcatheter ap-
proaches: First, no relevant aortic regurgitation was observed
in this patient series after implantation, most probably due to
the absence of annular calciﬁcations allowing for optimal valve
stent expansion. The implications of location and severity of
aortic valve calcium for paravalvular regurgitation were thor-
oughly investigated (17) and a negative impact on outcome is
well known (18), underlining the importance of this issue.
Second, in aortic stenosis, catheter manipulations of thecalciﬁed aortic valve and the diseased aorta seem to be asso-
ciated with an increase in stroke risk (19). The absence of
aortic leaﬂet calciﬁcations inmany cases of aortic regurgitation
may therefore lower the risk for thromboembolic events
during TAVI, especially in the absence of prior balloon aortic
valvuloplasty and rapid ventricular pacing. Third, the low
radial force of the JenaValve THV in combination with the
absence of balloon aortic valvuloplasty or the necessity for
post-dilation may lower the risk for conduction disturbances
related to the procedure if compared with the outcomes of
patients after TAVI for calciﬁed aortic valve stenosis (12).
An increase in aortic regurgitation has been described in
patients undergoing LVAD therapy with subsequent
recurrence of heart failure symptoms (20). Hence, 1 patient
underwent TAVI prior to scheduled LVAD implantation to
treat the moderate aortic regurgitation and allow for optimal
hemodynamic support, making this a promising hybrid
procedure for select heart failure patients.
Conclusions
To the best of our knowledge, this is the ﬁrst report on the
feasibility of TAVI in patients with noncalciﬁed aortic
regurgitation using the second-generation JenaValve THV.
Promising procedural and early results have been accom-
plished in this small patient series but larger patient numbers
and longer-term follow-up have to be awaited before
drawing ﬁnal conclusions.
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APPENDIX
For the supplemental video and its legend, please see the online version of
this paper.
